The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1361
Intravenous Acetaminophen (Ofirmev)
The full article is available to subscribers Subscriber Login   
Revised 4/12/11: In table 1, the cost of ketorolac is for a single 30-mg prefilled syringe.

The FDA has approved an intravenous (IV) formulation of acetaminophen (Ofirmev – Cadence) for use in patients ≥2 years old for management of pain either as monotherapy (mild to moderate pain) or with an opioid (moderate to severe pain) and for reduction of fever.

FORMULATIONS — An IV formulation of propacetamol, a prodrug of acetaminophen, has been available in Europe for more than 20 years, but needs reconstitution and has been associated with pain on injection. An IV formulation of acetaminophen itself that does not require reconstitution and is less likely to cause pain on injection has been available in Europe since 2002.

IV NONOPIOIDS FOR PAINKetorolac was the first nonsteroidal anti-inflammatory drug (NSAID) to become available in an injectable formulation in the US; it is marketed for short-term (up to 5 days) use. IV or intramuscular ketorolac is comparable ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Intravenous Acetaminophen (Ofirmev)
Article code: 1361c
 Electronic, downloadable article - $25